A- A A+

Whole body massage for newborns: A report on non-invasive methodology for neonatal opioid withdrawal syndrome. 

Rana D, Garde K, Elabiad MT, Pourcyrous M. 

J Neonatal Perinatal Med. 2022;15(3):559-565. doi: 10.3233/NPM-220989. PMID: 35599503.



Neonatal Abstinence Syndrome: Prevention, Management and Outcomes: From Birth to Adulthood. 

Allegaert K, Oei JL. 

Children (Basel). 2022 Jul 30;9(8):1151. doi: 10.3390/children9081151. PMID: 36010042; PMCID: PMC9406822.


Improving Public Health Surveillance for Neonatal Abstinence Syndrome in Rhode Island. 

St John K, Arias W. 

R I Med J (2013). 2022 Aug 1;105(6):57-59. PMID: 35882003.


Do small for gestational age infants have less severe neonatal abstinence syndrome? 

Friedman D, Zubair N, Favara MT, Lafferty M, Carola D, Adeniyi-Jones S, Solarin K, Aghai ZH. 

J Neonatal Perinatal Med. 2022 Jul 6. doi: 10.3233/NPM-221053. Epub ahead of print. PMID: 35811547.



Development of an abbreviated symptom score for the neonatal abstinence syndrome. 

Chervoneva I, Adeniyi-Jones SC, Blanco F, Kraft WK. 

J Perinatol. 2020 Jul;40(7):1031-1040. doi: 10.1038/s41372-020-0606-4. Epub 2020 Feb 19. PMID: 32076111; PMCID: PMC7319884.


Current research in pathophysiology of opioid-induced respiratory depression, neonatal opioid withdrawal syndrome, and neonatal antidepressant exposure syndrome. 

Baldo BA. 

Curr Res Toxicol. 2022 Jun 6;3:100078. doi: 10.1016/j.crtox.2022.100078. PMID: 35734228; PMCID: PMC9207297.


Global research production in neonatal abstinence syndrome: A bibliometric analysis. 

Zyoud SH, Al-Jabi SW, Shahwan MJ, Jairoun AA. 

World J Clin Pediatr. 2022 May 9;11(3):307-320. doi: 10.5409/wjcp.v11.i3.307. PMID: 35663005; PMCID: PMC9134155.


Morphine versus methadone for neonatal opioid withdrawal syndrome: a randomized controlled pilot study. 

Sutter MB, Watson H, Yonke N, Weitzen S, Leeman L. 

BMC Pediatr. 2022 Jun 15;22(1):345. doi: 10.1186/s12887-022-03401-3. PMID: 35705944; PMCID: PMC9202148.


A review of pregnancy-induced changes in opioid pharmacokinetics, placental transfer, and fetal exposure: Towards fetomaternal physiologically-based pharmacokinetic modeling to improve the treatment of neonatal opioid withdrawal syndrome. 

van Hoogdalem MW, Wexelblatt SL, Akinbi HT, Vinks AA, Mizuno T. 

Pharmacol Ther. 2022 Jun;234:108045. doi: 10.1016/j.pharmthera.2021.108045. Epub 2021 Nov 20. PMID: 34813863.



Implementation of a Standardized Clinical Definition of Opioid Withdrawal in the Neonate: Challenges and Opportunities. 

Jilani SM, Jones HE, Davis JM. 

JAMA. 2022;327(17):1643–1644. doi:10.1001/jama.2022.5406


Prenatal opioid-exposed infant extracellular miRNA signature obtained at birth predicts severity of neonatal opioid withdrawal syndrome. 

Mahnke AH, Roberts MH, Leeman L, Ma X, Bakhireva LN, Miranda RC. 

Sci Rep. 2022 Apr 8;12(1):5941. doi: 10.1038/s41598-022-09793-7. PMID: 35396369; PMCID: PMC8993911.


Improving Outcomes through a Neonatal Abstinence Syndrome Collaborative in Maryland. 

DiPietro B, Silcox K, Rost J, Woods L, Edwards EM, Buus-Frank M, Horbar J, Hudak M. 

Am J Perinatol. 2022 Apr 5. doi: 10.1055/a-1817-5522. Epub ahead of print. PMID: 35381608.


Prenatal smoking, alcohol and caffeine exposure and offspring externalizing disorders: a systematic review and meta-analysis. 

Haan, E, Westmoreland, KE, Schellhas, L, Sallis, HM, Taylor, G, Zuccolo, L, et al. 

Addiction. 2022; 1– 12. doi.org/10.1111/add.15858


Neonatal Abstinence Syndrome in North Carolina: Incidence and Characteristics among Infants and Mothers. 

Harward ML, Clontz AA, Vo TT, Jiroutek MR, Carter CA. 

N C Med J. 2022 Mar-Apr;83(2):142-146. doi: 10.18043/ncm.83.2.142. PMID: 35256478.


Individual and Combined Association Between Prenatal Polysubstance Exposure and Childhood Risk of Attention-Deficit/Hyperactivity Disorder. 

Garrison-Desany HM, Hong X, Maher BS, Beaty TH, Wang G, Pearson C, Liang L, Wang X, Ladd-Acosta C. 

JAMA Netw Open. 2022 Mar 1;5(3):e221957. doi: 10.1001/jamanetworkopen.2022.1957. PMID: 35275164; PMCID: PMC8917426.


The impact of opioid exposure during pregnancy on the human neonatal immune profile. 

Miller NW, Seman BG, Akers SM, Povroznik JM, Brundage K, Fang W, Robinson CM. The 

Pediatr Res. 2022 Mar 14:1–9. doi: 10.1038/s41390-022-02014-x. Epub ahead of print. PMID: 35288639; PMCID: PMC8920062.


Use of Phenobarbital to Treat Neonatal Abstinence Syndrome From Exposure to Single vs. Multiple Substances. 

Kushnir A, Garretson C, Mariappan M, Stahl G. 

Front Pediatr. 2022 Jan 31;9:752854. doi: 10.3389/fped.2021.752854. PMID: 35174112; PMCID: PMC8841756.


Determination of Prenatal Substance Exposure Using Meconium and Orbitrap Mass Spectrometry. 

Hernandez A, Lacroze V, Doudka N, Becam J, Pourriere-Fabiani C, Lacarelle B, Solas C, Fabresse N. 

Toxics. 2022 Jan 26;10(2):55. doi: 10.3390/toxics10020055. PMID: 35202242; PMCID: PMC8875502.


Clinical pharmacology and dosing regimen optimization of neonatal opioid withdrawal syndrome treatments. 

Tang F, Ng CM, Bada HS, Leggas M. 

Clin Transl Sci. 2021 Jul;14(4):1231-1249. doi: 10.1111/cts.12994. Epub 2021 May 1. PMID: 33650314; PMCID: PMC8301571.


Aberrant Feeding and Growth in Neonates With Prenatal Opioid Exposure: Evidence of Neuromodulation and Behavioral Changes. 

Yen E, Maron JL. 

Front Pediatr. 2022 Jan 21;9:805763. doi: 10.3389/fped.2021.805763. PMID: 35127598; PMCID: PMC8814597.


Gestational Age Alters Assessment of Neonatal Abstinence Syndrome. 

Amiri S, Nair J. 

Pediatr Rep. 2022 Jan 28;14(1):50-57. doi: 10.3390/pediatric14010009. PMID: 35225878; PMCID: PMC8883891.


Comparison of Two Morphine Dosing Strategies in the Management of Neonatal Abstinence Syndrome. 

Harris JB, Holmes AP. 

J Pediatr Pharmacol Ther. 2022;27(2):151-156. doi: 10.5863/1551-6776-27.2.151. Epub 2022 Feb 9. PMID: 35241987; PMCID: PMC8837209.


Implementation of Interprofessional Rounds Decreases Neonatal Abstinence Syndrome Length of Stay. 

McCarty T, Braswell E. 

J Pediatr Pharmacol Ther. 2022;27(2):157-163. doi: 10.5863/1551-6776-27.2.157. Epub 2022 Feb 9. PMID: 35241988; PMCID: PMC8837217.


Incidence of Neonatal Abstinence Syndrome (NAS) in Castilla y Leon (Spain). 

Moreno-Ramos M, Sánchez-Barba M, Sánchez RG, Mirón-Canelo JA, González-Nuñez V. 

Children (Basel). 2021 Dec 30;9(1):25. doi: 10.3390/children9010025. PMID: 35053650; PMCID: PMC8774299.


Infants of Mothers with Cocaine Use: Review of Clinical and Medico-Legal Aspects. 

Cestonaro C, Menozzi L, Terranova C. 

Children (Basel). 2022 Jan 5;9(1):67. doi: 10.3390/children9010067. PMID: 35053692; PMCID: PMC8774427.


Effects of Prenatal Methamphetamine Exposure on Birth Outcomes, Brain Structure, and Neurodevelopmental Outcomes. 

Zhang Y, Gong F, Liu P, He Y, Wang H. 

Dev Neurosci. 2021;43(5):271-280. doi: 10.1159/000517753. Epub 2021 Jun 17. PMID: 34139695.


Birth Outcomes of Neonates Exposed to Marijuana in Utero: A Systematic Review and Meta-analysis. 

Marchand G, Masoud AT, Govindan M, et al. 

JAMA Netw Open. 2022;5(1):e2145653. doi:10.1001/jamanetworkopen.2021.45653


Neonatal Opioid Withdrawal Syndrome (NOWS): A Transgenerational Echo of the Opioid Crisis. 

Weller AE, Crist RC, Reiner BC, Doyle GA, Berrettini WH. 

Cold Spring Harb Perspect Med. 2021 Mar 1;11(3):a039669. doi: 10.1101/cshperspect.a039669. PMID: 32229609; PMCID: PMC7919394.


Characterization of neonatal opioid withdrawal syndrome in Arizona from 2010-2017. 

Eaves ER, Barber J, Whealy R, Clancey SA, Wright R, Cocking JH, Spadafino J, Hepp CM. 

PLoS One. 2021 Jun 3;16(6):e0248476. doi: 10.1371/journal.pone.0248476. PMID: 34081702; PMCID: PMC8174702.


Neonatal Outcomes after Combined Opioid and Nicotine Exposure in Utero: A Scoping Review. 

Isaacs KR, Atreyapurapu S, Alyusuf AH, Ledgerwood DM, Finnegan LP, Chang KHK, Ma TX, Washio Y. 

Int J Environ Res Public Health. 2021 Sep 28;18(19):10215. doi: 10.3390/ijerph181910215. PMID: 34639512; PMCID: PMC8508043.